A5035723395- Pharmaceutical studies and practices
- Medication Adherence and Compliance
- Cystic Fibrosis Research Advances
- Growth Hormone and Insulin-like Growth Factors
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Veterinary Medicine and Surgery
- Antimicrobial Resistance in Staphylococcus
- Tuberculosis Research and Epidemiology
- Cardiovascular Disease and Adiposity
- Inflammatory Bowel Disease
- Immunodeficiency and Autoimmune Disorders
- Meat and Animal Product Quality
- Healthcare and Environmental Waste Management
- Pregnancy and Medication Impact
- Metabolism, Diabetes, and Cancer
- Infectious Diseases and Mycology
- Healthcare cost, quality, practices
- Microscopic Colitis
- Mycobacterium research and diagnosis
- Antibiotics Pharmacokinetics and Efficacy
- Animal Genetics and Reproduction
University Hospitals of Leicester NHS Trust
2021-2024
American Pharmacists Association
2024
North Carolina State University
2019
Non-tuberculous mycobacteria (NTM) infections predominantly present as pulmonary disease. Although relatively rare, 20–30% originate from extrapulmonary sites resulting in a wide range of clinical syndromes. Immunocompromised individuals are particularly susceptible. Clinical manifestations include skin and soft-tissue infections, lymphadenitis, musculoskeletal disseminated Diagnosing NTM is challenging, management complex, often involving combination multiple radiological microbiological...
Background: Vancomycin (VAN) protein binding in plasma is influenced by illness and age; hence, doses titrated according to total concentrations are fraught. In this study, model-estimated free VAN (EFVC) were compared with assumed (AFVC) neonates, children, adults the intensive care unit those on dialysis. Methods: Patient cohorts identified from hospital database. Demographics, clinical characteristics, concentrations, laboratory variables obtained electronic health records. EFVC was...
Therapeutic drug monitoring of infliximab (IFX) is important to optimise treatment inflammatory bowel disease (IBD). A recent IBD consensus statement recommends targeting trough serum concentrations >3 μg/mL, higher than our local recommendation >1 μg/mL. We therefore investigated the relationship between IFX and C reactive protein (CRP), faecal calprotectin (FCP), clinical outcomes anti-IFX antibody (AB) development as well influence concomitant thiopurine treatment.
In this paper we review three intra-luteal factors and their roles in the corpus luteum (CL). Insulin-like growth factor (IGF)-I, together with its receptor IGF-binding proteins (IGFBPs), represent an important control system CL. IGF-I is a product of small luteal cells has steroidogenic (i.e. luteotrophic) actions on large via type I receptor, while IGFBPs (e.g. BP-2 3; cells) generally inhibit IGF-Is actions. particularly early CL development (up to day 7 oestrous cycle) pig. Tumour...